^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NG-641

    i
    Other names: NG-641, bispecific anti-stromal T-SIGn virus, NG 641
    Associations

    News

    Trials
    Company:
    Akamis Bio
    Drug class:
    CD3 agonist, IFNα stimulant, FAP inhibitor, CXCL10 stimulant, CXCL9 stimulant
    Related drugs:
    Associations

    News

    Trials
    3ms
    STAR: First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral Vector (clinicaltrials.gov)
    P1, N=186, Active, not recruiting, Akamis Bio | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Aug 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases • Viral vector
    |
    NG-641
    3ms
    MOAT: A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov)
    P1, N=36, Active, not recruiting, Akamis Bio | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy
    |
    Keytruda (pembrolizumab) • NG-641
    3ms
    NEBULA: Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Akamis Bio | Recruiting --> Active, not recruiting | Phase classification: P1a/1b --> P1 | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: May 2024 --> Aug 2024
    Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • Combination therapy • Metastases • Viral vector
    |
    Opdivo (nivolumab) • NG-641
    over1year
    MOAT: A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov)
    P1, N=36, Recruiting, Akamis Bio | Trial completion date: Dec 2023 --> Oct 2024 | Trial primary completion date: Aug 2023 --> Sep 2024
    Trial completion date • Trial primary completion date • Combination therapy
    |
    Keytruda (pembrolizumab) • NG-641
    over1year
    NEBULA: Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (clinicaltrials.gov)
    P1a/1b, N=30, Recruiting, Akamis Bio | Trial completion date: Dec 2022 --> Jul 2024 | Trial primary completion date: Oct 2022 --> May 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases • Viral vector
    |
    Opdivo (nivolumab) • NG-641
    over2years
    NEBULA: Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (clinicaltrials.gov)
    P1a/1b, N=30, Recruiting, PsiOxus Therapeutics Ltd | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • NG-641
    3years
    NEBULA: Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (clinicaltrials.gov)
    P1a/1b, N=30, Not yet recruiting, PsiOxus Therapeutics Ltd
    Clinical • New P1 trial • Combination therapy
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • NG-641
    over3years
    MOAT: A Dose-escalating, Phase Ib Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov)
    P1, N=48, Not yet recruiting, PsiOxus Therapeutics Ltd
    New P1 trial
    |
    LIPI (Lipase I)
    |
    Keytruda (pembrolizumab) • NG-641